Navigation Links
Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sull'efficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
Date:6/25/2013

MILANO, June 25, 2013 /PRNewswire/ --

Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che mostrano l'efficacia superiore della combinazione fissa olmesartan/amlodipina rispetto alla combinazione perindopril/amlodipina nel controllo della pressione arteriosa centrale. SEVITENSION prende le mosse dai risultati del precedente studio CAFÉ-Conduit Artery Function Evaluation (parte dello studio ASCOT), che aveva mostrato come i trattamenti in combinazione fissa abbiano effetti differenti sulla pressione arteriosa centrale.

"Queste evidenze - ha dichiarato Luis Ruilope, direttore dell'Unità Antipertensiva dell'Ospedale 12 Ottobre di Madrid e coordinatore dello studio Sevitension - potrebbero spiegare la differenza dei risultati clinici fra i due gruppi dello studio ASCOT e fornire utili indicazioni per aiutare i medici a scegliere la miglior opzione di trattamento per gestire in maniera più efficace e conveniente l'ipertensione, proteggendo i pazienti dal rischio cardiovascolare. L'ambizione è quella di raggiungere l'obiettivo di controllare adeguatamente la pressione arteriosa nel 70% dei pazienti entro il 2015".

Gli inibitori dell'enzima di conversione dell'angiotensina (ACE-I) agiscono bloccando l'enzima che trasforma l'angiotensina I in angiotensina II, mentre gli ARB agiscono bloccando il recettore dell'angiotensina II, offrendo peraltro il vantaggio di minori effetti collaterali rispetto agli ACE-I, in particolare la tosse.

Daiichi Sankyo continua il proprio impegno nell'ipertensione e nello sviluppo dell'olmesartan. Lo studio SEVITENSION si è concentrato proprio sulla valutazione della combinazione fissa olmesartan/amlodipina.

Lo studio SEVITENSION ha analizzato la combinazione di 40 mg di
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Online Course Helps Employers Comply with OSHA’s Dec. 1, 2013, GHS Training Deadline
2. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
3. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
4. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
5. Retraction of Press Release Dated March 7, 2013, Regarding Recipient of Alumni Award from Johns Hopkins University
6. CANVUS Design Studio Specializes in Graphic Design and Commercials
7. Accelrys Materials Studio Release 6.1 Speeds Innovation with Enterprise Capabilities
8. Temple Run Gamers Have a New IOS Game To Play, Dream Bot Studios Explains
9. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
10. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
11. Il Ministero della sanità canadese ha concesso le indicazioni sulla salute rivendicate da cinque formulazioni probiotiche di Lallemand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... BETHESDA, Md., Sept. 16 Micromet, Inc. (Nasdaq: MITI ), ... inflammation and autoimmune diseases, today announced that its President and CEO, Dr. ... September 22, 2009 in New York City. A simultaneous webcast of ... , , ...
... ... RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential ... ... research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic ...
... , , CINCINNATI, Sept. 16 ... research organization, today announced the Company will participate in the upcoming ... Grand Hyatt New York Hotel in New York City. , ... , , Kendle,s formal presentation will be given ...
Cached Biology Technology:Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 2Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 3CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 2CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 3Kendle to Present at UBS Global Life Sciences Conference 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A new study that provides a snapshot of a ... of physical activity are strongly associated with being overweight or ... in fruits and vegetables did little to offset the effect ... who were mostly sedentary. Instead, exercise seemed to be the ...
... March 24 An experimental vaccine against an abnormal protein ... onset of inflammatory bowel disease (IBD) and in turn prevent ... of Pittsburgh School of Medicine. Their findings are reported this ... the American Association for Cancer Research. People with chronic ...
... A Worcester Polytechnic Institute (WPI) research team has ... Institutes of Health (NIH) to continue a groundbreaking study ... that will enable physicians to predict the likelihood of ... and strokes. Led by Dalin Tang, PhD, professor of ...
Cached Biology News:Rochester study connects workplace turmoil, stress and obesity 2Rochester study connects workplace turmoil, stress and obesity 3Rochester study connects workplace turmoil, stress and obesity 4Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
...
...
... PCR Cloning Kit offers the fastest ... cloning of blunt-end PCR products amplified ... includes the linearized and topoisomerase I-activated ... ligations without ligase (1). The pCR-Blunt ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: